Jaguar Health (JAGX) Life Sciences Virtual Investor Forum summary

Strategic partnerships and licensing

• Secured an $18 million upfront and $3 million milestone payment from a licensing deal with Future Pak, with up to $20 million in additional milestones, providing significant non-dilutive funding.

• Manufacturing of crofelemer remains in-house, creating a profit center and leveraging economies of scale.

• Future Pak's acquisition of Theratechnologies aligns with the target patient demographic, enhancing sales synergy for Mytesi.

• Mytesi and related assets are positioned for further business development opportunities.

Pipeline and clinical development

• Focused on late-stage clinical programs for rare diseases: pediatric microvillus inclusion disease (MVID) and short bowel syndrome/intestinal failure (SBS-IF).

• Proof of concept data showed up to 37% reduction in parenteral support for MVID and ~15.5% for SBS-IF patients.

• Pivotal MVID trial fully enrolled, aiming for FDA-fileable data by end of 2026 and NDA filing in early 2027.

• Orphan drug designation secured in both the US and Europe for MVID and SBS-IF.

• Breakthrough designation and PRIME applications planned to accelerate regulatory pathways.

Market opportunity and competitive landscape

• SBS-IF market projected to exceed $8 billion by 2033, with rare disease markets characterized by high value and strong patient advocacy.

• Existing competitor Gattex (GLP-2) is limited by safety profile and patient eligibility, while crofelemer offers a differentiated, non-growth hormone mechanism.

• Crofelemer's botanical guidance approval provides practical exclusivity and robust IP protection.